-

Analyst Rating Hits Snap (SNAP) Shares, Adding Pressure to Company Already Facing Ad Platform Lawsuit, According to Hagens Berman

SAN FRANCISCO--(BUSINESS WIRE)--Shares of social network Snap Inc. (NYSE: SNAP) fell 6.6% after investment firm Mizuho reportedly initiated coverage on the company with a Neutral rating and a $9 price target. Mizuho purportedly described the company as a “show-me story” and cited weak feedback from Snap’s advertising channels.

After Snap revealed an ad platform ‘execution error,’ its stock plunged 17% in a single day.

Share

This analyst action comes on the heels of a federal securities class action lawsuit filed against Snap and certain senior executives, alleging the company presented a misleading picture of its digital advertising platform's performance and future growth prospects.

Video: https://youtu.be/0cFMfKT71ec

Hagens Berman urges investors in Snap who suffered significant losses to submit your losses now.

Core Allegations of Snap Securities Fraud Lawsuit:

The securities class action alleges that the company experienced significant negative consequences from a major “execution error” related to a recent change in its ad platform but failed to disclose this crucial information to investors throughout the Class Period.

The alleged deception came to light on August 5, 2025, when Snap reported its Q2 2025 results. The company admitted it “shipped a change that caused some campaigns to clear the auction at substantially reduced prices”. This admission confirmed a significant slowdown in ad revenue growth, which had decelerated from 9% in Q1 to just 1% in April. News of the failure caused Snap’s stock price to tumble by approximately 17% the following day.

The lawsuit covers investors who purchased shares between April 29, 2025, and August 5, 2025.

Hagens Berman’s Investigation on Behalf of Investors

Hagens Berman, a prominent shareholder rights firm, is actively investigating the alleged claims and urges investors who suffered substantial losses to come forward.

“The lawsuit alleges that a major internal failure—the ‘execution error’—was concealed from investors. We’re focused on determining whether management knew but failed to timely disclose this core operational problem,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Snap and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Snap case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Snap should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SNAP@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contacts

Reed Kathrein, 844-916-0895

Hagens Berman

NYSE:SNAP

Release Versions

Contacts

Reed Kathrein, 844-916-0895

More News From Hagens Berman

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism. The report sent Corcept shares down, wiping ou...

Hagens Berman: Homebuyers Sue Rocket Mortgage and Affiliated Companies in Class Action Alleging Illegal Practices Inflating Home Prices

DETROIT--(BUSINESS WIRE)--A class-action lawsuit alleges homebuyers were illegally steered to use Rocket Mortgage, to their detriment, according to attorneys at Hagens Berman....

CoreWeave (CRWV) Faces Securities Class Action Over Denton Data Center Completion Delays, $14 Billion Market Cap Loss - Hagens Berman Investigates

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights firm, announces a securities class-action lawsuit against CoreWeave, Inc. (NASDAQ: CRWV) and several executives on behalf of investors who purchased CoreWeave securities between March 28 and Dec. 15, 2025. The lawsuit alleges that CoreWeave misled investors about delays in its Denton, Texas data center cluster, intended to support OpenAI operations. Hagens Berman is reviewing whether CoreWeave’s statements about its re...
Back to Newsroom